"Designing Growth Strategies is in our DNA"

Cardiovascular Therapeutics Market Size, Share and Global Trend By Drug Class (Anti-Hyperlipidemia, Anti-fibrinolytic, Anti-hypertensive, Others), Disease Type (Cardiac Arrhythmias, Arteriosclerosis, Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Others), Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies), and Forecast till 2026

Region : Global | Published Date: Upcoming | Report ID: FBI100379| Status : Upcoming



Cardiovascular disorders are considered to be one of the major causes of mortality and morbidity among the population worldwide. The blockage caused due to the deposition of fats on the inner walls of blood vessels prevents blood from flowing to heart or brain which leads to clot formation, strokes, arrhythmias, and heart failures. According to WHO, in 2015, it was estimated that around 17.7 million people died due to various cardiovascular diseases. A further distinction in lifestyle has enlarged the prevalence of obesity, which has further led to persistence increase in the prevalence of cardiovascular diseases. Innovations in the new drugs for treating cardiovascular disease is likely to upsurge the growth in cardiovascular therapeutics market.                                                                                                                                                

The growth of cardiovascular therapeutics market is majorly driven by growing demand and affordability for effective and novel drug therapies for treating various cardiovascular diseases. Novel oral anticoagulants are highly being embraced by patients for replacement of injectable anti-coagulants like Warfarin and Heparin in the management of thrombus formation. Moreover, the development of new peptide therapies for treating cardiovascular diseases (CVD) is likely to boost the market growth during the forecast period. In addition, an increase in the investments in the research and development activities has resulted in the emergence of potential pipeline candidates ready to capture the market share.

To get information on various segments, share your queries with us

On to the contrary, rigid drug regulatory process, high treatment cost, and various side effects associated with cardiovascular disease drugs are likely to hinder the market growth.

Key Players Covered:

Major companies involved in the global cardiovascular disease drug market include Pfizer, Inc., AstraZeneca, Merck & Co., Sanofi S.A., Novartis AG, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited., Bayer AG and other key players.




By Drug Class

  • Anti-hyperlipidemia
  • Anti-fibrinolytic
  • Anti-hypertensive
  • Anti-arrhythmic
  • Anti-coagulants

By Disease Type

  • Cardiac arrhythmias
  • Arteriosclerosis
  • Acute coronary syndrome
  • Myocardial infarction
  • Coronary artery disease
  • Peripheral artery disease
  • Hyperlipidemia
  • Hypertension
  • Cardiac failure diseases
  • Thrombosis

By Distribution Channel

  • Online pharmacies
  • Hospital pharmacies
  • Retail pharmacies

By Geography

  • North America (the USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of  Middle East & Africa)


In terms of drug class segmentation, anti-hypertensive drugs are anticipated to account for the largest market due to the increasing prevalence of heart disease and increasing incidents of hypertension and diabetes around the globe.

Key Insights:

  • Patent analysis
  • Overview of pipeline drugs
  • The Regulatory scenario for key countries/region
  • Key developments- mergers, acquisitions, and partnerships

Regional Analysis:

Geographically, the global Cardiovascular therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among them, North America is likely to secure the place as the market leader in cardiovascular drugs in the forecasting period. Widespread awareness of the various cardiovascular diseases and highly developed healthcare system in the US are the major contributing factors for the dominance of the region in the global cardiovascular therapeutics market. In 2019, Novartis AG. launched Entresto a combination of valsartan and sacubitril, which is mainly used for the treatment of heart failure. Growing partnerships between major key players for developing new products and high investments in healthcare domain by government authorities are likely to anticipate the expansion of market growth in the Asia Pacific region becoming a key revenue generator in the upcoming years.

Key Industry Developments

  • In March 2019, Novartis AG., launched Entresto which was designed specifically for the treatment of heart failure that helped in reduction in EF.
  • In December 2017, Medicure Inc. acquired an exclusive license to sell and market cardiovascular drug for the treatment of primary hyperlipidaemia or mixed dyslipidaemia in the U.S.
  • In October 2017, Sun Pharmaceutical Industries Ltd. launched generic version of Coreg CR. to treat various cardiovascular disease after gaining approval from FDA.

Cardiovascular Therapeutics Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017


  • 4850

Healthcare Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.